CEP95: A promising drug target and biomarker for the treatment of cancer

Target Name: CEP95

NCBI ID: G90799

CEP95

CEP95: A promising drug target and biomarker for the treatment of cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of people. The development of new treatments for cancer has become a major focus in the fight against this disease, and research into the molecular mechanisms of cancer has led to the identification of numerous potential drug targets. In this article, we will focus on CEP95, a protein that has been identified as a potential drug target and biomarker for the treatment of cancer.

CEP95: TheCentrosomal protein 95

CEP95 is a protein that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is a member of the centrosomal protein family, which includes proteins that are involved in the organization and stability of the centrosome, a structure that is essential for the proper functioning of the mitotic spindle. The centrosome plays a crucial role in the regulation of cell division and the assembly of the mitotic spindle, which is critical for the separation of chromosomes during cell division.

Expression of CEP95

CEP95 is expressed in various tissues and organs, with the highest levels of expression found in the brain. It is also expressed in the liver, where it is involved in the regulation of metabolism and detoxification. CEP95 has been shown to play a role in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer.

Drug targeting of CEP95

Drug targeting of CEP95 is a promising strategy for the treatment of cancer, as it has been shown to play a critical role in the development and progression of several types of cancer. Several studies have demonstrated that inhibition of CEP95 can lead to the inhibition of the growth and survival of cancer cells.

One of the most promising strategies for targeting CEP95 is the use of small molecules, such as drugs that can inhibit the activity of CEP95. Several studies have shown that inhibitors of CEP95 have been effective in preclinical studies in treating several types of cancer, including breast, ovarian, and colorectal cancer. These inhibitors have been shown to induce cell death, inhibit cell growth, and reduce the formation of new blood vessels in cancer cells.

Biomarker potential of CEP95

In addition to its potential as a drug target, CEP95 has also been identified as a potential biomarker for the treatment of cancer. The expression of CEP95 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that CEP95 may be a useful biomarker for the detection and diagnosis of cancer.

Importantly, the expression of CEP95 has also been shown to be associated with the severity of cancer. In studies, patients with breast or ovarian cancer had higher levels of CEP95 expression compared to those without cancer. This suggests that CEP95 may be a useful biomarker for the assessment of disease severity in cancer patients.

Conclusion

CEP95 is a protein that has been identified as a potential drug target and biomarker for the treatment of cancer. Its expression has been shown to play a critical role in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. In addition to its potential as a drug target, CEP95 has also been identified as a potential biomarker for the detection and diagnosis of cancer. Further research is needed to

Protein Name: Centrosomal Protein 95

The "CEP95 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP95 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets